首页> 外文OA文献 >Alzheimer-like changes in protein kinase B and glycogen synthase kinase-3 in rat frontal cortex and hippocampus after damage to the insulin signalling pathway
【2h】

Alzheimer-like changes in protein kinase B and glycogen synthase kinase-3 in rat frontal cortex and hippocampus after damage to the insulin signalling pathway

机译:胰岛素信号通路受损后大鼠额叶皮层和海马中蛋白激酶B和糖原合成酶激酶-3的阿尔茨海默病样变化

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The insulin-resistant brain state is related to late-onset sporadic Alzheimer's disease, and alterations in the insulin receptor (IR) and its downstream phosphatidylinositol-3 kinase signalling pathway have been found in human brain. These findings have not been confirmed in an experimental model related to sporadic Alzheimer's disease, for example rats showing a neuronal IR deficit subsequent to intracerebroventricular (i.c.v.) treatment with streptozotocin (STZ). In this study, western blot analysis performed 1 month after i.c.v. injection of STZ showed an increase of 63% in the level of phosphorylated glycogen synthase kinase-3α/β (pGSK-3α/β) protein in the rat hippocampus, whereas the levels of the unphosphorylated form (GSK-3α/β) and protein kinase B (Akt/PKB) remained unchanged. Three months after STZ treatment, pGSK-3α/β and Akt/PKB levels tended to decrease (by 8 and 9% respectively). The changes were region specific, as a different pattern was found in frontal cortex. Structural alterations were also found, characterized by β-amyloid peptide-like aggregates in brain capillaries of rats treated with STZ. Similar neurochemical changes and cognitive deficits were recorded in rats treated with i.c.v. 5-thio-d-glucose, a blocker of glucose transporter (GLUT)2, a transporter that is probably involved in brain glucose sensing. The IR signalling cascade alteration and its consequences in rats treated with STZ are similar to those found in humans with sporadic Alzheimer's disease, and our results suggest a role for GLUT2 in Alzheimer's pathophysiology.
机译:胰岛素抵抗性脑状态与迟发性散发性阿尔茨海默氏病有关,并且已在人脑中发现胰岛素受体(IR)及其下游磷脂酰肌醇3激酶信号通路的改变。这些发现尚未在与散发性阿尔茨海默氏病相关的实验模型中得到证实,例如,大鼠在用链脲佐菌素(STZ)进行脑室内(i.c.v.)治疗后显示神经元IR缺陷。在这项研究中,i.c.v。1个月后进行了蛋白质印迹分析。注射STZ后大鼠海马中磷酸化糖原合酶激酶3α/β(pGSK-3α/β)蛋白水平增加了63%,而未磷酸化形式(GSK-3α/β)和蛋白水平升高了63%激酶B(Akt / PKB)保持不变。 STZ治疗后三个月,pGSK-3α/β和Akt / PKB水平趋于下降(分别下降8%和9%)。这些变化是区域特定的,因为在额叶皮层中发现了不同的模式。还发现了结构性改变,其特征在于用STZ治疗的大鼠脑毛细血管中的β-淀粉样肽样聚集体。在经静脉注射治疗的大鼠中记录了类似的神经化学变化和认知缺陷。 5-thio-d-glucose,一种葡萄糖转运蛋白(GLUT)2的阻滞剂,该转运蛋白可能与脑葡萄糖感应有关。在用STZ治疗的大鼠中,IR信号级联改变及其后果与在散发性阿尔茨海默氏病的人类中发现的相似,我们的结果表明GLUT2在阿尔茨海默氏症的病理生理学中具有作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号